Publications by authors named "Y Kagiyama"
Background: Transradial access (TRA) is not a common vascular access in children. We have been performing TRA actively to reduce puncture complications, and the purpose of this study was to investigate the safety and efficacy of TRA in young children.
Methods: The study included 29 patients aged 5-12 years who underwent diagnostic catheterization at Kurume University Hospital.
Current status of transcatheter intervention for complex right ventricular outflow tract abnormalities.
Glob Cardiol Sci Pract
January 2024
Various transcatheter interventions for the right ventricular outflow tract (RVOT) have been introduced and developed in recent decades. Transcatheter pulmonary valve perforation was first introduced in the 1990s. Radiofrequency wire perforation has been the approach of choice for membranous pulmonary atresia in newborns, with high success rates, although complication rates remain relatively common.
View Article and Find Full Text PDFBackground: This study aimed to determine whether ongoing vascular inflammation presents in patients who had coronary artery aneurysms (CAAs) caused by Kawasaki disease (KD).
Methods: Subjects were 26 patients with a history of KD; 15 had giant CAA (gCAA) ≥ 8.0 mm and 11 had smaller CAA (smCAA) < 8 mm in the acute phase.
Introduction: Metastatic urothelial carcinomas are common in lung, liver, and lymph nodes. We present rare secondary tumor of the prostate metastasized from upper tract urothelial carcinoma.
Case Presentation: An 87-year-old man was diagnosed as urothelial carcinoma of left upper tract and bladder.
Article Synopsis
- Mantle cell lymphoma (MCL) is a rare type of cancer that often becomes resistant to treatment, like the drug ibrutinib, so new treatment options are needed.
- Researchers tested a new drug called OR-S1, which targets proteins called EZH1/2, and found that it worked better than ibrutinib in stopping tumor growth in mice with MCL.
- The study showed that OR-S1 affects how MCL cells grow and change, and it works by targeting a protein called CDKN1C that helps control the cell cycle, making it a potential new treatment for tough-to-treat MCL.